3.4.22.55 liver - -, 647460, 666298, 753185 3.4.22.55 lung - 647460 3.4.22.55 skeletal muscle low activity -, 647460 3.4.22.55 spleen - -, 647460 3.4.22.55 testis - -, 647460, 664286 3.4.22.55 ovary - 647603, 666898 3.4.22.55 brain fetal 647750 3.4.22.55 kidney kidney cortex 647754 3.4.22.55 ovarian granulosa cell - 647757 3.4.22.55 HeLa cell - 647760, 647763, 663875, 666511, 711715, 732733 3.4.22.55 JURKAT cell - 647763, 663875, 711697 3.4.22.55 astrocytoma cell - 663875 3.4.22.55 brain embryonic and adult 663875 3.4.22.55 brain embryonic and adult, highest expression in embryonic brain 663875 3.4.22.55 heart - -, 647460, 663875, 664548 3.4.22.55 kidney - -, 647460, 663875 3.4.22.55 THP-1 cell - 663875 3.4.22.55 thymus adult 663875 3.4.22.55 U-937 cell - 663875, 665952 3.4.22.55 germ cell - -, 664286 3.4.22.55 bladder - 664533 3.4.22.55 RT4 cell - 664533 3.4.22.55 cardiomyocyte - 664548 3.4.22.55 HCE-4 cell human esophageal cancer cell line 664753 3.4.22.55 HCE-7 cell human esophageal cancer cell line 664753 3.4.22.55 HCT-116 cell human colon cancer cell line 664753 3.4.22.55 LN-319 cell human malignant glioma cell line 664753 3.4.22.55 SW-480 cell human colon cancer cell line 664753 3.4.22.55 TE-2 cell human esophageal cancer cell line 664753 3.4.22.55 HeLa cell HeLa cervical carcinoma cell 664855 3.4.22.55 A-549 cell human lung adenocarcinoma cell 665247 3.4.22.55 HCT-116 cell human colon adenocarcinoma cell 665553 3.4.22.55 HeLa cell human cervix adenocarcinoma cell 665553 3.4.22.55 T3M4 cell human pancreatic cancer cell 665553 3.4.22.55 JURKAT cell JURKAT T-lymphocyte 665588 3.4.22.55 HCT-116 cell colon carcinoma cell line 666351 3.4.22.55 HeLa cell cervical carcinoma cell line 666351 3.4.22.55 Hep-G2 cell hepatoma cell line 666351 3.4.22.55 splenocyte - 666419 3.4.22.55 HEK-293T cell - 666511 3.4.22.55 corpus luteum at estrus, activity is 7.6fold greater in the old corpus luteum compared to new corpus luteum 666898 3.4.22.55 corpus luteum immunostaining for caspase-2 increases as the luteal phase progresses 666898 3.4.22.55 endothelial cell immunostaining for caspase-2 increases as the luteal phase progresses 666898 3.4.22.55 testis shift of caspase 2 from the cytoplasm in the sham-operated testis to the mitochondria in the testis after torsion 679114 3.4.22.55 ALVA-31 cell histone deacetylase inhibition leads to decreased protein kinase casein kinase 2 activity, which is followed by caspase-2 activation and partial cleavage of caspase-8 that sensitizes the tumor cell to TRAIL-induced apoptosis 684512 3.4.22.55 DU-145 cell histone deacetylase inhibition leads to decreased protein kinase casein kinase 2 activity, which is followed by caspase-2 activation and partial cleavage of caspase-8 that sensitizes the tumor cell to TRAIL-induced apoptosis 684512 3.4.22.55 LNCaP cell histone deacetylase inhibition leads to decreased protein kinase casein kinase 2 activity, which is followed by caspase-2 activation and partial cleavage of caspase-8 that sensitizes the tumor cell to TRAIL-induced apoptosis 684512 3.4.22.55 HMEC-1 cell thrombin initiates EMP generation from the human microvascular endothelial cell line HMEC-1. Caspase-2 plays a role in release of endothelial microparticles by controlling the proteolytic activation of ROCK-II 685783 3.4.22.55 DU-145 cell - 685908 3.4.22.55 LNCaP cell - 685908 3.4.22.55 acute T-lymphocytic leukemia cell treatment of melanoma cells with terfenadine induced DNA damage and caspases 2 activation. A selective inhibitor of caspase-2 (benzyloxycarbonyl-VDVAD-fluoromethylketone) protects melanoma cells from terfenadine-induced apoptosis 685967 3.4.22.55 ovary caspase-2L activationis induced by ionizing radiation (0.5 Gy) in the 1 day postpartum. Caspase-2-dependent activation of the mitochondrial apoptotic pathway is one of the mechanisms involved in the genotoxic stress-induced depletion of the primordial follicle pool 686001 3.4.22.55 BxPC-3 cell PS-341 (bortezomib) induces a dose-dependent apoptosis in association with reactive oxygen species generation and cleavage of caspase-2 to its 33- and 14-kDa fragments. PS-341-induced caspase-2 activation is attenuated by a selective pharmacological inhibitor of cathepsin B (R-3032). Caspase-2 regulates mitochondrial permeability 687504 3.4.22.55 fibroblast embryonic fibroblasts deficient for both Bax and Bak indicate the contribution of both Bax and Bak in mediating cell death induced by resveratrol and the existence of Bax/Bak-independent cell death possibly through caspase-8- or caspase-2-mediated mitochondria-independent downstream caspase processing 687509 3.4.22.55 HCT-116 cell caspase-2 activation occurs upstream of mitochondria in resveratrol-treated cells. The activated caspase-2 triggers mitochondrial apoptotic events by inducing conformational changes in Bax/Bak with subsequent release of cytochrome c, apoptosis-inducing factor, and endonuclease G. Caspase-2 contributes toward the mitochondrial translocation of Bid 687509 3.4.22.55 A-549 cell expression of c-Myc and caspase-2 are crucial for cytochrome c release from mitochondria during cytotoxic stress. Caspase-2 is important for cytosolic Bax to integrate into the outer mitochondrial membrane 687708 3.4.22.55 U2-OS cell - 687708 3.4.22.55 fibroblast - 688972 3.4.22.55 fibroblast caspase-2 is required for apoptosis induced by cytoskeletal disruption. Caspase-2 mediates apoptosis via Piddosome, Bid and Bax activation, and cytochrome c release 689290 3.4.22.55 NCI-H1299 cell caspase 2 activation is required for release of cytochrome c and cell death 689798 3.4.22.55 neuroblastoma cell - 701085, 711697 3.4.22.55 SK-N-BE(2) cell - 701085 3.4.22.55 H4 neuroglioma cell - 709626 3.4.22.55 coronary artery smooth muscle cell - 710625 3.4.22.55 HT-29 cell - 711679 3.4.22.55 MEF cell - 666419, 711697, 711715, 712540, 713566, 732048 3.4.22.55 thymocyte - 711697, 712540 3.4.22.55 embryonic fibroblast - 711715, 711831, 753185 3.4.22.55 HEK-293 cell - 711715 3.4.22.55 oocyte - 666298, 711820 3.4.22.55 melanoma cell line - 712665 3.4.22.55 HCT-116 cell - 713152, 717457, 731606 3.4.22.55 RAW-264.7 cell - 713348, 731559 3.4.22.55 JURKAT E-6.1 cell - 713545 3.4.22.55 NSCLC cell - 718112 3.4.22.55 bone marrow-derived macrophage - 731559 3.4.22.55 epithelial cell - 731596 3.4.22.55 A-549 cell - 732068, 732733 3.4.22.55 egg - 732099 3.4.22.55 hippocampus - 731274, 732560 3.4.22.55 bone marrow-derived dendritic cell - 732704 3.4.22.55 2008 cell - 732733 3.4.22.55 2008C13 cell - 732733 3.4.22.55 A-2780 cell - 732733 3.4.22.55 A2780/CDDP cell - 732733 3.4.22.55 H-1299 cell - 732733 3.4.22.55 H-460 cell - 732733 3.4.22.55 additional information isoform casp-2S is undetectable in the SKOV3, H-1299 and HCT-116 p53-deficient cells 732733 3.4.22.55 ovarian cancer cell - 732733 3.4.22.55 PEO-1 cell - 732733 3.4.22.55 PEO-4 cell - 732733 3.4.22.55 SKOV-3 cell - 732733 3.4.22.55 skeletal muscle caspase-2 activity transiently increases more than two-fold within 24 h following induction of differentiation 752842 3.4.22.55 lung adenocarcinoma cell caspase-2 levels are significantly reduced in human lung adenocarcinoma with wild-type p53 753176 3.4.22.55 hepatocyte - 753185 3.4.22.55 body wall - 753601 3.4.22.55 coelomocyte high expression level 753601 3.4.22.55 intestine - 753601 3.4.22.55 tentacle - 753601 3.4.22.55 retina - 753947